Examples include small molecule screens on the melanocyte lineage that identified 5‐nitrofuran compounds, which are also effective in human melanoma 127, and the changes caused by BRAFV600E;p53 at the embryonic level that identified leflunomide, which is currently in clinical trials for melanoma 126 (Clinical trials.gov identifier NCT01611675). The gene discussed is TP53; the disease is melanoma.